Open AccessUse of Peptide Thrombopoietin Receptor Agonist Romiplostim (Nplate) in a Case of Primary HIV-Associated Thrombocytopenia
Author(s) -
Mohammed Aslam,
Anthony P. Cardile,
George E. Crawford
Publication year - 2013
Publication title -
journal of the international association of providers of aids care
Language(s) - English
Resource type - Journals
eISSN - 2325-9582
pISSN - 2325-9574
DOI - 10.1177/2325957413502539
Subject(s) - romiplostim , thrombopoietin receptor , thrombopoietin , medicine , agonist , eltrombopag , immunology , antibody , receptor , immune thrombocytopenia , biology , haematopoiesis , genetics , stem cell
Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.